Compare Kinross Gold Corporation (KGC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs 10X Genomics Inc — how do they compare? Kinross Gold Corporation trades at $23.74 (market cap $27.62B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Kinross Gold Corporation is far larger — about 2.7× 10X Genomics Inc's market cap, and Kinross Gold Corporation pays a 0.69% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and 10X Genomics Inc for 91 Days on average.
| KGC | TXG | |
|---|---|---|
Market Cap | $27.62B | $10.07B |
Volume | 6,347,266 | 5,657,286 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $97.74 |
52-Week Low | $22.47 | $11.48 |
Typical Hold Time | 53 Days | 91 Days |
Enterprise Value | $25.70B | $9.59B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold Corporation (KGC) trades at $23.34, up 0.69% today, with strong fundamentals including a P/E of 8.87 and robust profitability metrics. Recent earnings have consistently beaten expectations, though technical indicators signal bearish momentum. The company reported $7.05B revenue and $2.39B net income for 2025, with cash flow from operations reaching $3.76B. However, production guidance cuts for 2026-2027 have pressured the stock, offset by increased shareholder returns targeting 50% of free cash flow.
KGC presents a mixed outlook: attractive valuation and earnings growth support upside to the $38.80 consensus price target, but near-term risks include operational setbacks at key mines and ongoing legal investigations. The stock's bearish technical trend and rising costs warrant caution, though institutional buying and high analyst buy ratings (58.63%) indicate underlying confidence in long-term value.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
